Life Science News

Sixth Wave Innovations Inc. (CSE: SIXW) (OTCQB: ATURF) (FSE: AHUH) ("Sixth Wave", "SIXW" or the "Company") is pleased to announce that it has released the Design for Manufacturing ("DFM") specifications to Advanced Extraction Systems Inc. located in Charlottetown Prince Edward Island for final engineering design and manufacturing of its Affinity™ product line for cannabis purification.

The release of the DFM is a major milestone and the design incorporates the lessons learned to date using two pilot systems with the intention of increasing the flexibility and reliability of the system and giving SIXW the first Good Manufacturing Process (GMP) qualified system for production and delivery. SIXW expects to receive the final design/build quotation along with a production timeline in the coming weeks as it continues its preparation for full-scale commercialization.

Sixth Wave plans to deliver the first commercial Affinity™ System (the "System") to Oregon-based Green Envy Extracts (the "Customer") in Q4 this year assuming no unforeseen manufacturing/long lead item issues. The Customer purchase agreement requires that SIXW operate the system for a period of 60 to 90 days, producing a high purity full-spectrum cannabinoid distillate. Thereafter, SIXW will complete the already executed purchase order for the sale and installation of two additional GMP qualified units at the Customer's sites. The Company expects that there will be quality/operational improvements that will be required as the first systems become operational on a commercial production basis. Once the first Affinity™ System has been thoroughly tested SIXW will begin to secure additional orders for delivery from customers in the pipeline. It is anticipated the Company will be able to deliver 3 or more Systems per quarter, depending on production capacity, during the remainder of 2022 with the ability to continue or expand delivery in 2022/2023. SIXW has arranged sufficient production capacity with AESI to meet or exceed our expansion schedule.

"We are very excited to start building our first production units and truly entering the cannabis industry. Taking the extra time to ensure that our Affinity™ System was thoroughly tested for deployment was a difficult but right decision. Barring unforeseen issues, we remain on a steady pace to satisfying our immediate customers' needs and those of this growing industry," stated Dr. Jonathan Gluckman, President and CEO of Sixth Wave. He went on to remark, "Developments in the legalization of cannabis in the United States are indicative of a growing market. Roll out of our Affinity™ Systems will correspond nicely with the timing and implementation of licensed producers in these new markets."

Overall, the Company believes that financial markets and consumer demand for cannabis-related products are bullish. The Company expects to see continued State-by-State legalization, which will promote the build-out of facilities resulting in the continued expansion of markets for the Affinity™ System.

About Sixth Wave

Sixth Wave is a nanotechnology company with patented technologies that focus on extraction and detection of target substances at the molecular level using highly specialized Molecularly Imprinted Polymers (MIPs). The Company is in the process of a commercial rollout of its Affinity™ cannabinoid purification system, as well as IXOS®, a line of extraction polymers for the gold mining industry. The Company is also in the development stages of a rapid diagnostic test for viruses under the Accelerated MIPs (AMIPS™) label.

Sixth Wave can design, develop and commercialize MIP solutions across a broad spectrum of industries. The company is focused on nanotechnology architectures that are highly relevant for the detection and separation of viruses, biogenic amines, and other pathogens, for which the Company has products at various stages of development.

For more information about Sixth Wave, please visit our website at: www.sixthwave.com

ON BEHALF OF THE BOARD OF DIRECTORS

"Jonathan Gluckman"
Jonathan Gluckman, Ph.D., President & CEO

For information, please contact the Company:
Phone: (801) 582-0559
E-mail: info@sixthwave.com

Cautionary Notes

This press release includes certain statements that may be deemed "forward-looking statements" including statements regarding the performance of the IXOS®, Affinity™, and AMIPs™ technologies. All statements in this release, other than statements of historical facts, that address future events or developments that the Company expects, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual events or developments may differ materially from those in forward-looking statements. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause the Company's actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. In particular, successful development and commercialization of the Affinity technology are subject to the risk that the technology may not prove to be successful in capturing cannabinoid targets more efficiently than legacy technology, uncertainty product development, the uncertainty of timing, lack of track record of developing products for these applications and the need for additional capital to carry out product development activities. The value of any products ultimately developed could be negatively impacted if the associated patent is not granted.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/86104

News Provided by Newsfile via QuoteMedia

Optimi Health Finalizes Partnership and Psilocybin Supply Agreement With ATMA Journey Centers

Optimi Health Finalizes Partnership and Psilocybin Supply Agreement With ATMA Journey Centers

Optimi Health Corp. ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce that it has entered into an exploratory supply agreement with ATMA Journey Centers ("ATMA"), a privately held facilitator of psilocybin-assisted therapy and practitioner training services for palliative care and mental health conditions based in Calgary, Alberta.

The Company has finalized an agreement which will supply psilocybin products to ATMA for future therapist initiatives and supply requirements.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Optimi Health Enters Into Psilocybin Supply Agreement With Filament Health

Optimi Health Enters Into Psilocybin Supply Agreement With Filament Health

Optimi Health Corp. ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce that it has entered into a supply agreement with Filament Health ("Filament") (OTCQB:FLHLF) (NEO:FH) (FSE:7QS), a clinical-stage natural psychedelic drug development company.

Optimi has been engaged by Filament to supply psilocybin mushrooms cultivated in Optimi's recently inaugurated 20,000 square foot EU-GMP Princeton, British Columbia facility in the form of whole, dried mushroom fruiting bodies for potential drug development, testing, and analysis by Filament's research team.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Optimi Health Signs Psilocybin Supply Agreement With Halucenex Life Sciences Inc.

Optimi Health Signs Psilocybin Supply Agreement With Halucenex Life Sciences Inc.

Optimi Health Corp. ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce that it has entered into a supply agreement with Halucenex Life Sciences Inc. ("Halucenex"), a wholly owned subsidiary of Creso Pharma of Australia (ASX: CPH). Halucenex is based in Windsor, Nova Scotia and is a life sciences company focused on researching novel psychedelic compounds, developing and licensing psychedelic compounds for the pharmaceutical and nutraceutical markets, and conducting clinical trials on the medical benefits of psychedelic medicine.

Additionally, Optimi wishes to confirm that the supply agreement pertains to the entirety of the Company's recently harvested first batch of psilocybe cubensis mushrooms at its Princeton, British Columbia facility. The mushrooms will be supplied to Halucenex in the form of whole, dried mushroom fruiting bodies.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Albert Labs

Albert Labs Appoints Principal Investigator for Real World Evidence Study for KRN-101

Albert Labs Appoints Dr Sara Tai as Principal Investigator for upcoming RWE Study on KRN-101

Albert Labs International Corp. ( Albert Labs (CSE: ABRT) (FSE: VB50), the "Company"), an R&D company developing mental health therapeutic medicines, is pleased to announce Dr. Sara Tai Senior Lecturer in Clinical Psychology from Manchester University, as Principal Investigator for its upcoming trial. The trial will evaluate the safety and efficacy of KRN-101, a psilocybin-based medicine, for the treatment of cancer-related distress, an indication thought to affect some 15 million patients in Europe and North America .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
two open palms hold a sphere representing the earth with water in the background

Sustainable Packaging: Increasing Demand for Natural Solutions

We only have one planet — and until recently we've done a poor job taking care of it.

The packaging industry is one of the sectors in which this is most evident. With a projected market size of US$1.13 trillion by 2030, it also represents one of the most significant sources of pollution in the world. Globally, we produce roughly 380 million tons of plastic per year. Single-use items such as grocery bags, bottles and packaging represent around 50 percent of that number.

To put this into context, the plastic waste produced by soft drink companies could cover 83 football fields a day, and the pollution footprint of packaging is at least as bad.

Keep reading...Show less
Billy Goat Brands CEO Tony Harris

Billy Goat Brands CEO Tony Harris: Venture Capital Supporting Sustainability

Billy Goat Brands CEO Tony Harris: Venture Capital Supporting Sustainabilityyoutu.be

Keep reading...Show less

Latest Press Releases

Related News

×